MUSTANG BIO, INC.
MBIOMustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is MUSTANG BIO, INC.'s next FDA catalyst?→
MUSTANG BIO, INC.'s (MBIO) next tracked catalyst is a Earnings expected November 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MBIO biotech catalysts?→
Add MBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MUSTANG BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.